Leest u ook de informatie over dr. Robert Gorter en het Medical Center Cologne onder deze informatie: Mijn ervaringen met dr.Robert Gorter en het Medisch Centrum Keulen. Een waarschuwing 

En Klik hier voor meer adressen van klinieken in Duitsland waar dendritische celtherapie wordt gegeven.

15 juli 2012: informatie en links hersteld in onderstaande informatie. Interessant is ook dit studierapport: Dendritic cell therapy for oncology roundtable conference: This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms.

9 juni 2010: ASCO 2010 en Citation: J Clin Oncol 28, 2010 (suppl; abstr e13063)

Een nieuwe fase I studie toont opnieuw aan dat dendritische celtherapie een mogelijke vervolgbehandeling kan zijn voor mesothelioma longkankerpatienten waarbij de eerste behandeling heeft gefaald. En belangrijk de therapie gaf geen ernstige bijwerkingen Het is een kleine studie: 14 patienten met mesothelioma in de longen graad IV deden mee. Het resultaat was dat er in drie gevallen sprake was van stabiele ziekte en 1 van een gedeeltelijke remissie. Vergelijkbaar met andere studies die hieronder staan, o.a. een studie met muizen en een fase I studie uit de Erasmus Rotterdam en Radboud. Hier het abstract van de nieuwe fase I studie zoals gepresenteerd op ASCO 2010:

Immunotherapy with dendritic cells as a second-line therapy in advanced pleural mesothelioma

Citation: J Clin Oncol 28, 2010 (suppl; abstr e13063)

Author(s): J. Nesselhut, D. Marx, R. Y. Chang, D. Lorenzen, N. Cillien, W. Goebel, F. Fändrich, T. Nesselhut; Institut fuer Tumortherapie, Duderstadt, Germany; Meridian Medical Group, New York, NY; Clinic for Applied Cellular Medicine, University Hospital SH, Kiel, Germany

Background: Malignant pleural mesothelioma (MPM) is an aggressive disease with an unfavorable prognosis. The current front-line treatment for nonoperable stages is cisplatinum in combination with pemetrexed chemotherapy. The reported median overall survival times are less than 15 months. After failure of first-line therapy there is currently no proven effective therapy, whereas potential side effects from further treatments may impair quality of life. In those cases, we report that immunotherapy with monocyte-derived dendritic cells (MoDC) can be effective without significant impact on life quality.

Methods: After isolating monocytes from peripheral blood of n=14 patients with stage 4 MPM who failed first-line chemotherapy, MoDC were generated using standard protocols. The MoDC were primed on day 5 with tumor-lysate and co-cultured with toll-like receptor ligands to induce a TH1-polarization of the MoDC. In one case, an allogeneic cell line lysed by the oncolytic Newcastle disease virus (NDV) was used. This patient received an NDV injection one day before the DC administration. In general, the MoDC were harvested on day 7 and administered to the patients, intradermally.

Results: We were able to induce a clinical response in 29% of the patients (n=3 stabilization, 1 partial remission). The median survival after onset of DC-therapy was 7 months (1-26 months) and 24 months (7-33 months) after primary diagnosis. The therapy was well tolerated without having any major side effect. Interestingly, the patient showing a partial remission received the NDV-modified vaccine. IFN-gamma Elispot analyses from patients who received NDV injections and NDV-modified MoDC show that MoDC primed with NDV-lysed tumor cells can induce a specific CD4 and CD8 T-cell response against the NDV-lysed tumor cells whereas healthy donors show no specific T-cell response. 

Conclusions: Immunotherapy with dendritic cells may prolong the overall survival of patients with MPM after failure of first-line therapy without significant impact on the quality of life. For the first time, we demonstrated that NDV is able to infect MPM cells, leading to lysis of these cells.

16 april 2 Nijmegen010: Bron: Am J Respir Crit Care Med. 2010 Feb 18.

Het Erasmus Medisch Centrum Rotterdam meldt dat een eerste fase I studie bij 10 patienten met een ongeneeslijke vorm van longkanker namelijk asbestkanker - mesothelioom hoopgevende resultaten geeft. 1 patient is na vier jaar nog steeds in leven vertelde onderzoeksleider dr. Joachim Aerts aan het Algemeen Dagblad.

Geen van de 10 deelnemende patienten had bijwerkingen behalve dan de koorts die dendritische celtherapie altijd oproept. Over resultaten op verloop van de kanker zelf worden nog geen mededelingen gedaan door de onderzoekers in het Erasmus Medisch Centrum Rotterdam. Daarvoor is het nog te vroeg aldus onderzoeksleider Dr. Joachem Aerts.

Consolidative Dendritic Cell-Based Immunotherapy Elicits Cytotoxicity Against Malignant Mesothelioma

Joost P Hegmans¹, Joris D. Veltman¹, Margaretha E Lambers¹, I. Jolanda M. de Vries², Carl G. Figdor², Rudi W Hendriks¹, Henk C. Hoogsteden¹, Bart N. Lambrecht³, and Joachim G. Aerts^4*

¹ Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ² Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands, ³ Respiratory Medicine, Ghent University, Ghent, Belgium; Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ⁴ Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands; Pulmonary Medicine, Amphia Hospital, Breda, Netherlands

Rationale: Earlier we have demonstrated that dendritic cell-based immunotherapy induced protective antitumor immunity with prolonged survival in mice. However, the clinical relevance is still questioned. We designed a clinical trial using chemotherapy followed by antigen-pulsed dendritic cell vaccination in mesothelioma patients

Objectives: The aim of this study was to assess the safety and immunological response induced by the administration of tumor lysate-pulsed dendritic cells in mesothelioma patients.

Methods: Ten patients with malignant pleural mesothelioma received three vaccinations of clinical-grade autologous dendritic cells intradermally and intravenously at two-week intervals after chemotherapy. Each vaccine was composed of 50x10⁶ mature dendritic cells pulsed with autologous tumor lysate and keyhole limpet hemocyanin (KLH) as surrogate marker. Delayed-type hypersensitivity activity to tumor antigens and KLH was assessed, both in vivo and in vitro. Peripheral blood mononuclear cells during the treatment were analyzed for immunological responses. Main Results: Administration of dendritic cells pulsed with autologous tumor lysate in mesothelioma patients was safe with moderate fever as the only side effect. There were no grade 3 or 4 toxicities associated with the vaccines or any evidence of autoimmunity. Local accumulations of infiltrating T cells were found at the site of vaccination. The vaccinations induced distinct immunological responses to KLH, both in vitro and in vivo. Importantly, after three vaccinations, cytotoxic activity against autologous tumor cells was detected in a subgroup of patients.

Conclusions: This study demonstrated that autologous tumor lysate-pulsed dendritic cell-based therapy is feasible, well-tolerated, and capable of inducing immunological response to tumor cells in mesothelioma patients. www.clinicaltrials.gov NCT00280982

dendritic, mesothelioma, modc, erasmus, rotterdam, lysate, netherlands, autologous, pulsed, immunotherapy

---

• Mesothelioma: Dendritische celtherapie bij muizen met mesothelioom (asbestkanker) geeft hoopvolle resultaten, aldus onderzoekers in Erasmus Rotterdam.